Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR9879278

— · cohortSQ2

d6defdba-0d7b-5497-af77-8fa23dfc9f9b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ2
subtype
cohortSQ2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • G2M_CHECKPOINT+0.370
  • WNT_BETA_CATENIN_SIGNALING+0.340
  • E2F_TARGETS+0.310
  • ESTROGEN_RESPONSE_LATE+0.280
  • MTORC1_SIGNALING+0.280
  • KRAS_SIGNALING_DN+0.270
  • ESTROGEN_RESPONSE_EARLY+0.260
  • APICAL_SURFACE+0.210
  • TNFA_SIGNALING_VIA_NFKB+0.180
  • MITOTIC_SPINDLE+0.170

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
  • DNA_REPAIR-0.240
  • PANCREAS_BETA_CELLS-0.210
  • ALLOGRAFT_REJECTION-0.170
  • MYOGENESIS-0.170
  • ANGIOGENESIS-0.160
  • COAGULATION-0.150
  • UV_RESPONSE_DN-0.150
  • COMPLEMENT-0.100
  • HYPOXIA-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
153c767aa-2609-45c7-90ad-c0204f3c2b24
colon-landscapes@1
——0.687
2SRR15069616
head-neck@1
——0.618
3TCGA-34-5232-01A-21R-1820-07
lung-landscapes@6
—cohortSQ10.604
4C3N-03051
lung-landscapes@6
—cohortSQ10.602
5TCGA-22-0944-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.598
6TCGA-CQ-5323-01A-01R-1686-07
head-neck@1
——0.596
7TCGA-G2-A3IB-01A-11R-A20F-07
bladder-landscape@3
——0.583
8TCGA-44-5643-01A-01R-1628-07
lung-landscapes@6
—cohortSQ20.577
9C3N-03425
lung-landscapes@6
—cohortSQ10.574
10SRR10900586
melanoma-umap@29
——0.573

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
G2M_CHECKPOINT0.370Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.340Inavolisib— uncovered
E2F_TARGETS0.310Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.280Idelalisib— uncovered
MTORC1_SIGNALING0.280Inavolisib— uncovered
KRAS_SIGNALING_DN0.270Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.260Inavolisib— uncovered
APICAL_SURFACE0.210Temsirolimus— uncovered
TNFA_SIGNALING_VIA_NFKB0.180Inavolisib— uncovered
MITOTIC_SPINDLE0.170Inavolisib— uncovered
SPERMATOGENESIS0.170Inavolisib— uncovered
UV_RESPONSE_UP0.160Idelalisib— uncovered
ANDROGEN_RESPONSE0.150Inavolisib— uncovered
HEDGEHOG_SIGNALING0.150Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.140Remibrutinib— uncovered
P53_PATHWAY0.130Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.100Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.080Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.080Inavolisib— uncovered
PEROXISOME0.080Idelalisib— uncovered